AMELIO GILBERT F 4

What Happened

• Director Amelio Gilbert received a grant of 60,000 derivative securities (stock options) from Galectin Therapeutics, Inc. on January 16, 2026. The filing reports the award at $0.00 per share (derivative grant); total cash value is not listed. This is an award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-16; filing date: 2026-01-21 (filed within the SEC two-business-day window).
• Amount: 60,000 stock options reported as acquired at $0.00 (derivative).
• Vesting: Options vest 100% on December 31, 2026 (Footnote F2).
• Plan: Options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan (Footnote F1).
• Shares beneficially owned after the transaction: not specified in this Form 4.
• No indication of an immediate sale or cashless exercise in this filing.

Context

• This is a grant/award of options to a director—common for compensation and retention. It does not reflect an open-market purchase (which some investors view as a stronger bullish signal). The options vest in full at year-end 2026, so they are not currently exercisable/convertible into shares until vesting conditions are met.